CNTA (Centessa Pharmaceuticals) Cash-to-Debt : 4.11 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Centessa Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2024 was 4.11.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Centessa Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Centessa Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.28 Med: 4.11 Max: 7.86
Current: 4.11

During the past 6 years, Centessa Pharmaceuticals's highest Cash to Debt Ratio was 7.86. The lowest was 1.28. And the median was 4.11.

CNTA's Cash-to-Debt is ranked worse than
57.72% of 1483 companies
in the Biotechnology industry
Industry Median: 7.56 vs CNTA: 4.11

Centessa Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Centessa Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Centessa Pharmaceuticals Cash-to-Debt Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

1.28

7.86

5.64

3.03

4.11

Centessa Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial												3.03	2.67	3.44	6.12	4.11

Competitive Comparison of Centessa Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Centessa Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Centessa Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Centessa Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	482.177	/	(0	+	117.226)
	=	4.11

Centessa Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	482.177	/	(0	+	117.226)
	=	4.11

Centessa Pharmaceuticals (NAS:CNTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Centessa Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0ACX:UK 260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Executives

David M Chao	officer: Chief Administrative Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain	officer: General Counsel	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Gregory M Weinhoff	officer: Chief Financial Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha	director, officer: Chief Executive Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson	officer: Chief People Officer	C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
Tia L Bush	officer: Chief Quality Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Harris Rotman	officer: SVP Regulatory Affairs	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David J Grainger	officer: Chief Innovation Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman	officer: Chief Technology Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mathias Hukkelhoven	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De	director	C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH